black market semaglutide June 8, 2026: Reckless physicians prescribing experimental, weight loss drugs: “Why are we waiting?” – Partnership for Safe Medicines Market Overview: GLP-1 Agonists and

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimers disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

In a Bank of America note published on Monday, the analyst argues that brand mail pharmacy margins can be 5-10% (and in many cases pharmacies are losing money on GLP-1 scripts), which are significantly lower than the 50% gross margins we estimate HIMS is capturing in its GLP-1 portfolio. It is unlikely that HIMS will follow Ros lead to partner with brand manufacturers, the analyst added, because HIMS differentiation and success is tied to its own brand equity for its products and selling branded pharmaceutical drugs would both hurt margins and cannibalize its core products. Diversifying Beyond the Major GLP-1 Drugs Hims could also look to broaden its weight loss offerings, leveraging its established telehealth platform to incorporate non-drug-based solutions

It has also shown potential benefits for digestive health, supporting the lining of the stomach and intestines

Now when you complicate things further by not eating as much...you've got a gastrodisaster in the making

Sourris KC, Yao H, Jerums G, Cooper ME, Ekinci EI, Coughlan MT